Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAV versus DA for newly diagnosed adult acute myeloid leukemia
ChiCTR2100045780Phase 3Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of venetoclax, daunorubicin and cytarabine in acute myeloid leukemia (AML) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Complete remission. Started May 2021; status: recruiting.
02
Drugs
venetoclaxdaunorubicincytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2100045780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045780.